^
    Back
    Association details:
    Biomarker:MET exon 14 mutation
    Cancer:Non Small Cell Lung Cancer
    Drug:BPI-9016M (c-MET inhibitor, AXL inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC

    Excerpt:
    ...- Must have evidence of positive c-Met protein expression by IHC from either local data or the results of molecular pre-screening evaluations；Must haved evidence of MET exon 14 skipping alterations in blood and/or tissue samples....
    Trial ID:
    NCT02929290
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    BMC Cancer
    Title:

    Safety, efficacy and pharmacokinetics of BPI-9016M in c-MET overexpression or MET exon 14 skipping mutation patients with locally advanced or metastatic non-small-cell lung cancer: a phase Ib study

    Published date:
    04/11/2023
    Excerpt:
    In this two-part multicenter phase Ib study, eligible patients with locally advanced or metastatic NSCLC harboring c-MET overexpression or MET exon 14 skipping mutation were enrolled...Only one partial response (PR) patient was observed at a dose of 600 mg QD in Part A. In Part B, DCR was 75.0% (3/4, 95% CI 19.4–99.4%).
    DOI:
    https://doi.org/10.1186/s12885-022-10500-y
    Trial ID:
    NCT02929290